



HPAP-152 Donor Summary

HPAP	152	UNOS	
Recovery OPO	INOP - Indiana Donor Network	Allocation Via	UPENN <input type="checkbox"/> nPOD <input checked="" type="checkbox"/>
Age (years)	50	DCD	YES <input checked="" type="checkbox"/> NO <input type="checkbox"/>
Race	White: Not Specified	DBD	YES <input type="checkbox"/> NO <input checked="" type="checkbox"/>
Sex	M <input type="checkbox"/> F <input checked="" type="checkbox"/>	Admission to Cross Clamp	140 Hours 41 Mins.
ABO (Rh)	O	Cross Clamp Time	05/10/2023 21:13 EDT
BMI (Kg/m²)	32.334	Cold Ischemia Time*	15 Hours 30 Mins. WIT 22 mins
Weight (kg)	79.7000		
Height (cm)	157.00		
Cause of Death	CEREBROVASCULAR/STROKE	Preservation Solution	UW <input checked="" type="checkbox"/> HTK <input type="checkbox"/> Servator B
Mechanism of Injury	INTRACRANIAL HEMORRHAGE/STROKE	Organs Recovered	Heart <input type="checkbox"/> Kidney <input checked="" type="checkbox"/> Lung <input type="checkbox"/> Pancreas <input checked="" type="checkbox"/> Liver <input checked="" type="checkbox"/> Intestine <input type="checkbox"/>
Cardiac Arrest/Downtime	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/> 2 minutes	Intraoperative time lapse from liver to pancreas removal from the peritoneal cavity:	<input type="text"/> Hours <input type="text"/> Mins. NA
CPR / Time	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/> 2 minutes	Organs Discarded	Heart <input type="checkbox"/> Kidney <input type="checkbox"/> Lung <input type="checkbox"/> Pancreas <input type="checkbox"/> Liver <input type="checkbox"/> Intestine <input type="checkbox"/>
Total Est. Downtime	2 minutes	Blood Culture	24 Hour Result – No Growth
Date /Time of Admission	05/05/2023 00:32 EDT	PHS High Risk	YES <input type="checkbox"/> NO <input checked="" type="checkbox"/>
		Acute Lung Injury	Mild degree of lower lung field airspace infiltrates.

*Cold Ischemia time is calculated from time of cross clamp to start of enzyme perfusion for islet isolation.



HPAP-152 Donor Summary

Medical History:

		Duration	Medications	Compliance
Type of Diabetes	T2DM	4 years	Diet and exercise	Yes
History of cancer	-----	-----	-----	-----
CAD	-----	-----	-----	-----
Hypertension	yes	4 years		
Hyperlipidemia	-----	-----	-----	-----
Autoimmune disease	-----	-----	-----	-----
Family History	CAD <input checked="" type="checkbox"/> Father died of heart attack at a younger age	Diabetes <input checked="" type="checkbox"/> Mother type 2	Auto immune disease <input type="checkbox"/>	Others:
Surgical History:	sinus surgery and 2 c sections			
Comments:	Medical Hx: deep cough and mucus a week earlier Social Hx: Half a glass to one wine socially for 42 years			

Hemodynamic Profile

Average BP During Hospitalization (mmHg)	116/67	
Average Low BP During Hospitalization	NA	Duration: NA
Average BP in OR (mmHg)	NA	
Average Low BP in OR (mmHg)	NA	Duration: NA
Average HR in OR (bpm)	NA	
ABG-pH range	7.43 – 7.5	

INTERVENTION

Blood Products/Meds Transfused Before Organ Recovery

Product	Amount (ml)	Units	Total (ml)
Fresh Frozen Plasma	-----	-----	-----
PRBCs	-----	-----	-----
Platelets	-----	-----	-----
Norepinephrine (Levophed)	NA	NA	NA
Vasopressin	NA	NA	NA
Neo-Synephrine	NA	NA	NA
Epinephrine	NA	NA	NA
Phenylephrine	NA	NA	NA
Dopamine	NA	NA	NA



HPAP-152 Donor Summary

Blood Products/Meds Transfused Intraoperative

Product	Amount (ml)	Units	Total (ml)
Fresh Frozen Plasma	-----	-----	-----
PRBCs	-----	-----	-----
Platelets	-----	-----	-----
Norepinephrine (Levophed)	-----	-----	-----
Vasopressin	-----	-----	-----
Neo-Syneprine (phenylephrine)	-----	-----	-----
Epinephrine	-----	-----	-----
Dopamine	-----	-----	-----
Heparin	-----	30,000	-----

Initial Autoantibody Screening (nPOD): ELISA

Not performed for HPAP-T2D program

GAD-65	IA-2
ND	ND

Confirmatory results: Radioimmuno Assay (RIA)

	GAD-65 (unit/ml)	IA-2 (unit/ml)	Insulin AAB (unit/ml)	ZnT8 (unit/ml)
Results	0	0	0.002	0.000
Cut-off values	20	5	0.010	0.020

*Sample obtained at time of organ recovery.

	C-peptide (ng/ml)	Proinsulin
Results	3.95	NA

*Sample obtained at time of organ recovery.

HLA (OPO)*

Class 1	A	1	3	Class II	DR	17	15
	B	7	8		DR51	5*01	N-Negative
	C	07	No second antigen detected		DR52	3*01	N-Negative
	Bw4	Negative			DR53	N-Negative	N-Negative
	Bw6	Positive			DQB1	2	6
					DQA1	01	05
				DPB1	01:01	04:01	
				DPA1	01	02	
Comment:							

HPAP-152 Donor Summary



Confirmatory HLA (UPENN)*

Not performed for HPAP-T2D program

Class 1	A				Class II	DRB1		
	B					DRB3		
	C					DRB4		
						DRB5		
						DQB1		
						DQA1		
						DPB1		
						DPA1		

*HLA typing performed using NGS

Infectious Disease Serology

Test	Result	Hemo/Plasma Dilution Status	
		Qualified	Non-Qualified
EBV IgG	Pending	✓	-
EBV IgM	Pending	✓	-
CMV	Negative	✓	-
HBcAb	Negative	✓	-
HBsAg	Negative	✓	-
HCV Ab	Negative	✓	-
HIV I/II	Negative	✓	-
Syphilis	Negative	✓	-
Procleix Ultrio	NA	-	-
Ultrio HBV (HBV NAT)	Negative	✓	-
Ultrio HCV (HCV NAT)	Negative	✓	-
Ultrio HIV (HIV NAT)	Negative	✓	-
Toxoplasma Ab	Pending	✓	-
SARS-CoV-2	Not Detected	✓	-
Coronavirus NL63	Detected!		



HPAP-152 Donor Summary

Laboratory Panel

	Initial	Peak	Terminal
Na (mEq/L) (135-145)	138	157	149
Creatinine (<1.5)	0.5	0.91	0.89
Glucose (mg/dL) (60-150)	420	420	146
HbA1C%	10.5	-----	-----
Total bilirubin (0-1.0)	1.2	1.2	0.3
SGOT (AST) (0-40)	18	26	26
SGPT (ALT) (5-35)	16	16	15
Alkaline phosphatase (45-110)	57	62	62
Serum Amylase (23-851)	19	25	24
Serum Lipase (0-80)	94	94	71
WBC (THO/uL) (4.5-11.0)	18.9	18.9	8.7
Hgb (g/dL) (12-16)	12.8	12.8	9.1
Platelets (THO/uL) (150-350)	227	227	184
INR (<2.0)	1	1.1	1

Urinalysis

	1 st	2 nd	3 rd	4 th
Glucose	Negative	Negative	NA	NA

Medications During Hospitalization

Steroids**	-----
Diuretics	40mg Lasix IVP
T3 Protocol	-----
T4 Protocol*	-----
Insulin**	-----
Antihypertensive	-----
Vasodilators	-----
DDAVP**	-----
Total parenteral nutrition	N
Other	Unasyn 3gm q6h, Fentanyl @100mcg/hr, propofol@20mcg/kg/min
	Specify

*T4 protocol: Levothyroxine, (20 mcgs), Solumedrol (2 gms,) Dextrose 50%, (1 amp), Regular Insulin (20u), Vasopressin (1 unit)

Mi Z, Novitzky D, Collins JF, Cooper D KC. The optimal hormonal replacement modality selection for multiple organ procurement from brain-dead organ donors. Clinical Epidemiology 2015;7 17-27.

** Excluding T4 Protocol